The Pacific Brain Tumor Center at Santa Monica, Calif.-based Pacific Neuroscience Institute will serve as the leading enrollment site for Medicenna Therapeutics' clinical trial.
Five notes:
1. Medicenna Therapeutics is conducting a study for its MDNA55. The open-label, non-randomized, multi-center phase 2 study assesses the safety and efficacy of convection-enhanced delivery of its new bioengineered targeted therapeutic.
2. Adult patients who are no longer responding to first line chemotherapy after surgery are available to receive MDNA55, which is directly infused into the brain at the site of the tumor.
3. The therapeutic and direct infusion method is designed to achieve better drug delivery and efficacy to target tumor cells while reducing side effects associated with systemic and generalized delivery methods typical of standard therapies.
4. During the trial, surgeons will map the patient's tumor through specialized computer software and 3D imaging to determine optimal therapeutic coverage of the entire tumor and surrounding brain regions.
5. Achal Singh Achrol, MD, and Santosh Kesari, MD, PhD, are leading the study at Pacific Neuroscience Institute. The institute is one of seven sites across the country offering the clinical trial.